{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:05:02Z","timestamp":1788905102819,"version":"build-2803163510"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T00:00:00Z","timestamp":1404950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1038\/hr.2014.118","type":"journal-article","created":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T01:58:46Z","timestamp":1404957526000},"page":"799-800","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Possible benefits of azilsartan compared with other angiotensin II type 1 receptor blockers"],"prefix":"10.1038","volume":"37","author":[{"given":"Shin-ichiro","family":"Miura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Saku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,10]]},"reference":[{"key":"BFhr2014118_CR1","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.2174\/1381612811319170005","volume":"19","author":"S Imaizumi","year":"2013","unstructured":"Imaizumi S, Miura S, Yahiro E, Uehara Y, Komuro I, Saku K . Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers. Curr Pharm Des 2013; 19: 3002\u20133008.","journal-title":"Curr Pharm Des"},{"key":"BFhr2014118_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1470320310370852","volume":"12","author":"S Miura","year":"2011","unstructured":"Miura S, Karnik SS, Saku K . Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 2011; 12: 1\u20137.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"BFhr2014118_CR3","doi-asserted-by":"crossref","unstructured":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253\u2013392.","DOI":"10.1038\/hr.2014.20"},{"key":"BFhr2014118_CR4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/hr.2012.8","volume":"35","author":"H Rakugi","year":"2012","unstructured":"Rakugi H, Enya K, Sugiura K, Ikeda Y . Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012; 35: 552\u2013558.","journal-title":"Hypertens Res"},{"key":"BFhr2014118_CR5","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/hr.2014.86","volume":"37","author":"M Takahara","year":"2014","unstructured":"Takahara M, Shiraiwa T, Shindo M, Arai A, Kusuda Y, Katakami N, Kaneto H, Matsuoka T, Shimomura I . Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial. Hypertens Res 2014; 37: 852\u2013857.","journal-title":"Hypertens Res"},{"key":"BFhr2014118_CR6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.110.163402","volume":"57","author":"WB White","year":"2011","unstructured":"White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S . Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413\u2013420.","journal-title":"Hypertension"},{"key":"BFhr2014118_CR7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1751-7176.2010.00425.x","volume":"13","author":"GL Bakris","year":"2011","unstructured":"Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, Cao C, Kupfer S . The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011; 13: 81\u201388.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"BFhr2014118_CR8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.110.176636","volume":"336","author":"M Ojima","year":"2011","unstructured":"Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, Kubo K, Fuse H, Imura Y, Kusumoto K, Nagaya H . In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336: 801\u2013808.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFhr2014118_CR9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/hr.2012.147","volume":"36","author":"S Miura","year":"2013","unstructured":"Miura S, Okabe A, Matsuo Y, Karnik SS, Saku K . Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res 2013; 36: 134\u2013139.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr2014118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2014118","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2014118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:13:33Z","timestamp":1684415613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr2014118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,10]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["BFhr2014118"],"URL":"https:\/\/doi.org\/10.1038\/hr.2014.118","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,10]]},"assertion":[{"value":"10 July 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KS and SM have received grants and lecture honoraria from Daiichi-Sankyo Co. Ltd., MSD, Dainippon Sumitomo Pharma Co. Ltd., Takeda Pharma Co. Ltd., Novartis Pharma, Boehringer Ingelheim and Astellas Pharma Inc. KS is a Chief Director, and SM is a Director of NPO Clinical and Applied Science, Fukuoka, Japan. KS has an Endowed Department of \u2018Department of Molecular Cardiovascular Therapeutics\u2019 supported by MSD, Co. LTD. SM belongs to the Department of Molecular Cardiovascular Therapeutics supported by MSD, Co. LTD.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}